{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:03:00Z","timestamp":1790348580718,"version":"4.1.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10147-026-03119-7","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:50:29Z","timestamp":1782859829000},"page":"1419-1421","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; camizestrant for breast cancer, ivosidenib for biliary tract cancer, subcutaneous isatuximab and talquetamab plus teclistamab for multiple myeloma, isotretinoin for neuroblastoma, selpercatinib for pediatric RET-altered tumors, tafasitamab for lymphoma, and tislelizumab and durvalumab for gastric cancer"],"prefix":"10.1007","volume":"31","author":[{"given":"Noriomi","family":"Matsumura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"3119_CR1","unstructured":"Pharmaceuticals and Medical Devices Agency (2026) List of approved drugs (in Japanese). https:\/\/www.pmda.go.jp\/review-services\/drug-reviews\/review-information\/p-drugs\/0010.html Accessed on Jun 26, 2026"},{"key":"3119_CR2","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1056\/NEJMoa2502929","volume":"393","author":"FC Bidard","year":"2025","unstructured":"Bidard FC, Mayer EL, Park YH et al (2025) First-line camizestrant for emerging ESR1-mutated advanced breast cancer. N Engl J Med 393:569\u2013580. https:\/\/doi.org\/10.1056\/NEJMoa2502929","journal-title":"N Engl J Med"},{"key":"3119_CR3","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Macarulla T, Javle MM et al (2020) Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21:796\u2013807. https:\/\/doi.org\/10.1016\/S1470-2045(20)30157-1","journal-title":"Lancet Oncol"},{"key":"3119_CR4","unstructured":"Pharmaceuticals and Medical Devices Agency (2026) Electronic package insert for Tibsovo Tablets 250\u00a0mg (in Japanese). https:\/\/www.info.pmda.go.jp\/go\/pack\/4291090F1022_1_03\/ Accessed on Jun 26, 2026"},{"key":"3119_CR5","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1200\/JCO-25-00744","volume":"43","author":"S Ailawadhi","year":"2025","unstructured":"Ailawadhi S, \u0160pi\u010dka I, Spencer A et al (2025) Isatuximab subcutaneous by on-body injector versus isatuximab intravenous plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma: phase III IRAKLIA study. J Clin Oncol 43:2527\u20132537. https:\/\/doi.org\/10.1200\/JCO-25-00744","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"3119_CR6","doi-asserted-by":"publisher","first-page":"10038","DOI":"10.1200\/JCO.2026.44.16_suppl.10038","volume":"44","author":"A Makimoto","year":"2026","unstructured":"Makimoto A, Fujisaki H, Takahashi Y et al (2026) A study of the safety, efficacy, and pharmacokinetics of SPJ-101CA as maintenance therapy for newly diagnosed high-risk neuroblastoma. J Clin Oncol 44(16suppl):10038. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.10038","journal-title":"J Clin Oncol"},{"key":"3119_CR7","unstructured":"Pharmaceuticals and Medical Devices Agency (2026) Electronic package insert for Retevmo Tablets 40\u00a0mg and 80\u00a0mg (in Japanese). https:\/\/www.info.pmda.go.jp\/go\/pack\/4291075F1028_1_04\/ Accessed on Jun 26, 2026"},{"key":"3119_CR8","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","volume":"21","author":"G Salles","year":"2020","unstructured":"Salles G, Duell J, Gonz\u00e1lez-Barca E et al (2020) Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 21:978\u2013988. https:\/\/doi.org\/10.1016\/S1470-2045(20)30225-4","journal-title":"Lancet Oncol"},{"key":"3119_CR9","unstructured":"Pharmaceuticals and Medical Devices Agency (2026) Electronic package insert for Minjuvi for Intravenous Infusion 200\u00a0mg (in Japanese). https:\/\/www.info.pmda.go.jp\/go\/pack\/4291485D1023_1_02\/ Accessed on Jun 26, 2026"},{"key":"3119_CR10","doi-asserted-by":"publisher","first-page":"e078876","DOI":"10.1136\/bmj-2023-078876","volume":"385","author":"MZ Qiu","year":"2024","unstructured":"Qiu MZ, Oh DY, Kato K et al (2024) Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double-blind, phase 3 trial. BMJ 385:e078876. https:\/\/doi.org\/10.1136\/bmj-2023-078876","journal-title":"BMJ"},{"key":"3119_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","volume":"393","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, Al-Batran SE, Wainberg ZA et al (2025) Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med 393:217\u2013230. https:\/\/doi.org\/10.1056\/NEJMoa2503701","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"3119_CR12","doi-asserted-by":"publisher","first-page":"S1623","DOI":"10.1016\/j.annonc.2025.09.096","volume":"36","author":"J Tabernero","year":"2025","unstructured":"Tabernero J, Al-Batran SE, Wainberg ZAA et al (2025) Final overall survival (OS) and the association of pathological outcomes with event-free survival (EFS) in MATTERHORN: a randomised, phase III study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric \/ gastroesophageal junction (G \/ GEJ) adenocarcinoma. Ann Oncol 36(Suppl 2):S1623\u2013S1624. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.096","journal-title":"Ann Oncol"},{"key":"3119_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMoa2514752","volume":"394","author":"S Kumar","year":"2026","unstructured":"Kumar S, Mateos MV, Ye JC et al (2026) Dual targeting of extramedullary myeloma with talquetamab and teclistamab. N Engl J Med 394:51\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2514752","journal-title":"N Engl J Med"},{"key":"3119_CR14","unstructured":"Pharmaceuticals and Medical Devices Agency (2026) Revisions of PRECAUTIONS (FY2026). https:\/\/www.pmda.go.jp\/english\/safety\/info-services\/drugs\/revision-of-precautions\/0014.html Accessed on Jun 26, 2026"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03119-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03119-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03119-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T16:35:43Z","timestamp":1784997343000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03119-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3119"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03119-7","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"30 June 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}